Cutaneous And Systemic Leishmaniasis Market Segmented By pentavalent antimonials, antifungal drugs and anti-lesihmanial/antimicrobial drugs in oral, injectable, and topical Route of Administration with cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis Indication
Industry: Healthcare
Published Date: June-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 215
Report ID: PMRREP28225
The Global Cutaneous & Systemic Leishmaniasis Market value is projected to exceed US$ 411.1 million by the year 2028 at a steady CAGR of 2.90%. The increasing prevalence of Cutaneous & Systemic Leishmaniasis in tropical regions and the growing awareness regarding prevention and treatment of the disease are the major factors driving the growth of this market.
| Attribute | Key Insights |
|---|---|
|
Cutaneous & Systemic Leishmaniasis Market Size (2022) |
US$ 345.4 Mn |
|
Projected Market Value (2028) |
US$ 411.1 Mn |
|
Global Market Growth Rate (2022-2028) |
2.90% CAGR |
|
Share in parent market |
0.80% |
Cutaneous & Systemic Leishmaniasis is a disease that is prevalent mostly in the tropical regions. Rise in per capita income, increased awareness about the disease, increase in the healthcare expenditure, as well as an increase in the investments for research purposes are driving market growth and are expected to do the same throughout the forecast period.
A combination of several cutaneous and systemic leishmaniasis drugs has resulted in a higher percentage of effectiveness among several cutaneous and systemic trial groups that were treated with medications. Some combinations have also resulted in curing cutaneous and systemic leishmaniasis completely. Hence, this factor is likely to drive the growth of the Cutaneous and Systemic Leishmaniasis Market throughout the forecast period.
Several players in the cutaneous and systemic leishmaniasis markets are substantially investing in research activities to develop novel treatment alternatives. Furthermore, a wide range of drugs and therapies for the treatment of cutaneous and systemic leishmaniasis are currently under clinical trials, with almost all trial outcomes expected to be good. These initiatives are expected to create new opportunities for the treatment of cutaneous and systemic leishmaniasis.
Several governments around the globe are investing heavily in healthcare infrastructure and this is likely to drive the market for cutaneous and systemic leishmaniasis. Apart from this, several private health insurance providers are providing several reimbursement policies for the seamless and successful treatment of cutaneous and systemic leishmaniasis. Furthermore, people now have the freedom to select the type of reimbursement policy that is likely to provide the most advantages.
The treatment of Cutaneous & Systemic Leishmaniasis is very high due to the drugs being very expensive. Apart from this, the drugs used for the treatment can also cause serious adverse effects. However, new treatment options are being developed and it is expected to give a high degree of therapeutic measures against these diseases and also reduce the side effects.
“Decrease in the Demand of Cutaneous & Systemic Leishmaniasis due to lockdown”
The covid-19 outbreak had a negative impact on the global economy and it hurt the growth of the Cutaneous & Systemic Leishmaniasis Market because there was a drop in the demand for Cutaneous & Systemic Leishmaniasis drugs and treatment because healthcare facilities around the world were burdened with millions of Covid-19 positive patients. However, the demand increased again when the situation improved in 2021.
The Cutaneous & Systemic Leishmaniasis market is highly competitive and consists of significant major players that dominate the market. Several market players are implementing new and differentiating strategies to meet product demand and dominate the regional market. The market players are focusing on adopting new strategies and policies, such as effective technological & distributorship collaborations, promoting research & development for the development of products for the treatment of cutaneous & systemic leishmaniasis and product lunches, etc.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
US$ Mn/Bn for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
By Distribution Channel |
|
Key Companies Profiled |
|
|
Customization & Pricing |
Available upon Request |
Cutaneous & Systemic Leishmaniasis Market by By Drug Class
Cutaneous & Systemic Leishmaniasis Market By Route of Administration
Cutaneous & Systemic Leishmaniasis Market By Indication
Cutaneous & Systemic Leishmaniasis Market By Distribution Channel
Cutaneous & Systemic Leishmaniasis Market by Region
To know more about delivery timeline for this report Contact Sales
In 2022, the Cutaneous & Systemic Leishmaniasis Market stands at USD 345.4 million, and it is expected to reach USD 411.1 million by 2028 at a CAGR of 2.90%.
Cutaneous & Systemic Leishmaniasis Market exhibited a 2.90% CAGR between 2013 and 2021.
High Cost of Treatment and Chances Of Side Effects are the key restraints in the Cutaneous & Systemic Leishmaniasis Market.
High Clinical Cure Rate with Combinational Drug Therapy and Increased Investments for Research are the key factors driving the growth of the market.
Gilead Sciences Inc., Profounda Pharmaceuticals, Knight Therapeutics Inc., Janssen Global Services LLC, and Albert David Ltd, are among the top players in the market.
